PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

US approves Pfizer COVID-19 vaccine for children aged 12 to 15

Pfizer and partner company BioNTech have announced an expanded emergency use authorisation (EUA) for their COVID-19 vaccine from the US Food and Drug Administration to include children aged 12 to 15 years.
In a statement, the companies said that their COVID-19 jab is the first to be authorised in the US for use in this younger age group.
The expanded EUA is based on data from a Phase III clinical trial that enrolled 2,260 participants aged 12 to 15 years.
Previously announced topline results from this trial showed that the vaccine had an efficacy of 100% in participants with and without prior COVID-19 infection, as well as ‘robust’ antibody responses.
The vaccine was also found to be generally well-tolerated in this trial, with participants to be monitored for long-term protection and safety for an additional two years following their second dose.
Pfizer and BioNTech have submitted this data for scientific peer review for potential publication and also submitted the results to global regulators – including the European Medicines Agency (EMA).
“Since securing the EUA in December for individuals 16 years and older, we have been working tirelessly to get our COVID-19 vaccine authorised around the world so that governments can provide it to as many people as possible,” said Ugur Sahin, chief executive officer and co-founder of BioNTech.
“Our work is not yet complete, as we continue our research into the use of our vaccine in paediatric populations. Our goal is to submit data for pre-school and school-age children in September,” he added.
Pfizer and BioNTech are also currently evaluating the safety and efficacy of their COVID-19 vaccine in children aged six months to 11 years of age.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026